Methodological approaches to identifying and assessing risks of socially responsible activities of pharmaceutical companies
DOI:
https://doi.org/10.24959/uekj.20.28Keywords:
social responsibility, risk, identification of risks, risk management, pharmaceutical companyAbstract
The aim of the study is to identify the current types of risks inherent in the socially responsible activities of pharmaceutical companies, and to develop methodological approaches to their classification in accordance with international standards and taking into account the specifics of the functioning of pharmaceutical industry entities.
Materials and methods: analysis, synthesis, empirical methods, control survey method, modeling method.
Results. Based on the results of the analysis, a list of risks that may arise as a result of socially responsible activities by pharmaceutical industry entities was determined. As a result of the content analysis, classification characteristics of risks of social responsibility of the pharmaceutical business are determined. The risks of social responsibility were grouped according to classification characteristics. A survey of experts was conducted on the importance of certain types of risks of socially responsible activities of pharmaceutical companies. It is justified that modern pharmaceutical companies require modern methodological tools and organizational support for effective risk management of socially responsible activities by identifying these risks, assessing them and developing mechanisms for their minimization.
Conclusions. It has been proved that, together with the existence of significant strategic advantages in the implementation of socially responsible activities by pharmaceutical companies, this activity has a significant list of risks. These risks it is necessary to identify, reveal, estimate and operate them for increase in efficiency of social responsibility of pharmaceutical business. It was revealed that a certain range of risks of social responsibility are not manageable, they cannot be avoided, and their existence is due to the natural laws of the development of the pharmaceutical business and the desire of pharmaceutical companies to improve their own reputation and competitiveness. That is, today, for every pharmaceutical company that goes along the path of social responsibility, it is necessary to use modern methodological tools to identify, assess and manage the risks of social responsibility of the pharmaceutical business to ensure the conditions of sustainable socio-economic development.References
Bowen, H. R. (1953). Social responsibilities of the businessman. New York: Harper & Brothers.
Carroll, A. B. (1979). A Tree–Dimensional Conceptual Model of Corporate Performance. Academy of Management Review, 4 (4), 497–505.
Carroll, A. B. (1991). The pyramid of corporate social responsibility: Toward the moral management of organizational stakeholders. Business Horizons, 34 (4), 39–48.
Carroll, A. B. (2004). Managing ethically with global stakeholders: A present and future challenge. Academy of Management Executive, 18 (2), 114–120.
Davis, K. (1967). Understanding the social responsibility puzzle. Business Horizons, 10 (4), 45–50.
Davis, K. (1973). The Case for and Against Business Assumption of Social Responsibilities. Academy of Management Journal, 16 (2), 312–322.
Davis, K. (1960). Can Business Afford to Ignore Social Responsibilities? California Management Review, 2 (3), 70–76.
Zhuk, M. S., Shkurat. M. S., Lukianikhin V. O. (2014). Proceeding from Ekonomichni problemy staloho rozvytku: materialy mizhnar. nauk.-prakt. konf., (6–8 trav. 2014 r.). (pp. 271–272). Sumy.
Melashich, Zh., Starinecz, I. Strakhovij klub KNEU. Available at: http://pck.kneu.edu.ua/?p=174.
Zarichkova, M. V. (2016). Research of existing risks with employees of pharmacy institutions and classi fication of risks by different types of safety. Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 4, 32–37.
Cherkashyna, А. V., Kotvitska A. A. (2014). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 3, 36–42.
Tkachenko, N. O., Chervonenko, N. M., Knysh, Ye. H. (2013). Zaporozhskii med. zhurn, 2, 76–82.
Tolochko, V. M., Zarichkova, M. V. (2014). Proceeding from Sotsialna farmatsiia : stan, problemy ta perspektyvy: mizhnar. nauk.-prakt. Internet-konf. (17–20 berez. 2014 r.). (pp. 128–132). Kharkiv.
Governance Risk Compliance. Available at: https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Governance-Risk-Compliance/ dttl-grc- exploring-strategic-risk.pdf.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).